Listen Now

Angel Scale Biotech: Learn More Investing modest sums and copious energy, Ben Littauer helps tech companies sprout. His focus is startups that do the most good for the world. Founders and angel investors value Ben’s advice greatly. Sponsored by Purdue University entrepreneurship and Peter Fasse, patebt attorney at Fish and Richardson. Highlights: Sal Daher Introduces Ben Littauer Discovering Angel Groups Why Be an Angel Investor? Startups That Ben Littauer Has Invested In " It started off as being a soft robotic glove that allows a stroke survivor to move their hand ... measure how it's doing, and do multiple repetitions" The Importance of Coachability "The stuff that you and I invest in now are people inventing new things and there are no right answers" Sal's Angel Investing Journey "Jeff helped me realize that ... where I should be focusing all my energies is in these early-stage companies" "Aquaculture is the future of food" Advice for Potential Investors Topics: angel investing strategies, raising money, discovering entrepreneurship

Angel Scale Biotech: Learn More AI is coming for the pesky chores of bookkeeping. Enrico Palmerino, founder of VC-backed Botkeeper, relates how machine learning is helping accountants and their clients. Compelling founder with a great story. Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson. Sal Daher Introduces Enrico Palmerino What Botkeeper Does Why Efficient Bookkeeping Matters What Sets Botkeeper Apart Growing Clientele “We're venture backed. We've raised a total of about 90 million to date. We just closed our C round...” The AI Revolution The Statistics of Bookkeeping Challenges and How They're Dealt With Adapting to New Technologies Enrico Palmerino Had a Lot of Entrepreneurship in His Family Advice for Starting a Startup Evolving with Your Environment Topics: robotics/Ai, founding story, product

Angel-Scale Biotech: Learn More Bacterial growth in an IV caused a kid to lose his legs. Shocked by the tragedy, young physician Maryam Soomro began researching solutions. Her startup, TuCann, now uses black phosphorus tech from RMIT, Australia's MIT, to fight infection. Heartening! Sponsored by Purdue University entreprenuership and Peter Fasse, patent attorney at Fish and Richardson. Highlights: Sal Daher Introduces Maryam Soomro The IV Issue Black Phosphorus: How it Works Using Reactive Oxygen Species to Eliminate Bacterial Infection Creating a Startup: Where to Begin Where Will TuCann be Based? Getting a License For Use of Materials How TuCann Came About From Research to Entrepreneurship Topics: biotech, techstars, discovering entrepreneurship 

Opportunities in angel-scale biotech: Learn More It can take days to identify the cause of a bacterial infection; Ed Goluch, PhD founded QSM Diagnostics to change that. QSM now has a device that can detect a bacteria of interest in minutes. Ed updates us on the headway QSM has made since his first interview, Diagnosis in Minutes.  Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson. Highlights: Sal Daher Introduces Ed Goluch How QSM Diagnostics Came About Quorum Sensing Molecules: What Are They? Redirecting From Human To Animal Diagnostics Getting the Product Off the Ground Mail-in Test Kits Speeding Things Up at the Veterinary Offices Academic Founder to Founding CEO Persevering Through COVID Setbacks Animal Data Will Eventually Lead to Human Based Devices Greater Market in Animals Due to People Prioritizing Their Pets "The other interesting thing, lot of our sales are actually going to mobile vets" Getting the Word Out QSM Diagnostics Receives Prestigious Award Topics: founding story, product, discovering entrepreneurship

Discover angel-scale biotech: Learn More Eduardo Jorgensen founded Medicsen to improve the care of people with diabetes. Witnessing the struggles of patients taking insulin inspired Eduardo to leave medicine and build a device and an app to simplify the control of blood sugar by patients. Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish & Richardson Highlights:   Sal Daher Introduces Eduardo Jorgensen, Founder of Medicsen What Medicsen is all About The Suggin App and What it Does Making an Insulin Device That Does Not Require Needle Injection Discussing Product Patents Sonophoresis: Sound Based Drug Delivery Raising the Funds for the Company The Role Models Behind the Startup "Even if you're comfortable getting out of your comfort zone, doing that as a dad, it's a hard thing to do." Funding for Angel Investors Making Medicsen Profitable Deep Dive into the Suggin App How the Product Works With the App Perseverance Regardless of Low Funds and No Business Experience   Topics: Biotech, Discovering Entrepreneurship, Founding Story

Angel-scale biotech: Learn More While at Harvard Medical School, Senan Ebrahim was deeply affected by witnessing a still birth. Convinced better data could have avoided the tragedy, he founded Delfina Care with Priyanka Vaidya from EMOTIV, the EEG platform, and his brother Ali Ebrahim, PhD, a former Tech Lead at Google. Senan and Priyanka joined me for a great chat about the exciting things happening in digital health.   Highlights:   Sal Daher Introduces Senan Ebrahim and Priyanka Vaidya of Delfina Senan Ebrahim Was Interviewed in a Prior Episode Titled “Hikma Health” Obstetricians Are Flooded with Data from Pregnant Patients Leading to Poor Outcomes Priyanka Vaidya’s Experience with Gestational Diabetes Highlighted the Need to Coordinate Care “...I realized discontinuity of care is a major problem.” “Delfina wants to be that one place that integrates all of these discrete sources of data so that the mom stays in the center of the care...” Integrating Health Data Shows Up in Interviews with Jeremy Wiygul, MD of Pela Health and Ryan Hess of Connective Health “...how are we going to take better care of the four million pregnant moms in 2023 than we did in 2022?” Senan Reached Out to Priyanka for Product Savvy and to His Brother Ali for Experience Building Sophisticated Data Models The Patient Journey at Delfina “This data is being enriched as the patient travels along the journey.” Machine Learning Is Just Starting to Do Useful Things in Medicine Like Identifying a Stroke Quickly or Predicting Preeclampsia Incentives Are Aligned in Pregnancy Care; Nobody Wants Babies to End Up in Intensive Care What Delfina Means by “Closing the Loop” in Patient Care Delfina’s Platform Is Actually Live at a Practice in California Commercialization Will Focus Initially on Under-Served Populations How the Name “Delfina” Came About The Founding Story of Delfina Care Topics: biotech, product, robotics / AI

Angels helping biotech startups: Learn More Exited founder Sean Kevlahan, PhD tells the story of Quad Technologies and how an interesting polymer contributed to the explosion of cell therapies in the last decade. Sean gives great advice for biotech founders and investors, and joins Armon Sharei in my pantheon of chemical engineers who are gifted communicators. Sponsored by Purdue University entrepreneurship and Peter Fasse, patents attorney at Fish & Richardson. Highlights: Sal Daher Welcomes Sean Kevlahan, PhD, Founder of Quad Technologies “...how do you release a cell from a substrate [underlying substance] without killing a cell?” “Magnetic beads have been around for a while. Researchers use them to separate cells.” How Do You remove the Magnetic Beads without Killing the Cell? Quad Technologies’ Polymer Made It Possible to Remove the Magnetic Beads “When we first started out Quad, we focused on the academic markets.” The Success of CAR T-cell Therapies Opened Up an Opportunity for Quad -Help Multiply the CAR T-cells Emily Whitehead, the First Patient Treated with CAR T-cell Therapy, Is in Remission for Ten Years The Aha Moment that Put Quad Technologies on the Map Sean Kevlahan’s Epiphany Led to a Pivot and Product/Market Fit Ran Into Someone from Bio-Techne at the JP Morgan Conference & Discovered the Strategic Fit Bio-Techne Acquired Quad Technologies in July of 2018 – Investors Did Very Well Sal Daher Is Eager to Learn About Sean Kevlahan’s Stealth Startup “Even in biotech winter exited founders who have had this kind of success are very much in demand.” Sean Kevlahan’s Grandfather Was an Entrepreneur, a Successful Restauranteur Sean’s Entrepreneurship Activated by Hitting the “3-Year Wall” Doctoral Students Experience Quad’s Polymer Used to Be Just Coating for Microfluidics Chips; Sean and Adam Hatch Imagined Many More Uses “We went from obviously, biotech, which just makes the most sense to coating the undersides of boats for marine biofouling.” Due to MassChallenge, Quad’s Tech Was Used in the International Space Station Sean Kevlahan Speaks Well of Northeastern University’s Tech Transfer Office Quad Raised $ 6 Million Which Qualifies as Angel-Scale The Vital Importance of Clear Messaging by Life Science Founders – Lose the Jargon! “...I have to do a mental check, and making sure that I'm not being too jargony.” Biotechnologies Are Multiplying and Creating a Cascade of Opportunities Quad Raised $ 6 Million from Fifteen Angel Investors Siamab Raised $ 14 Million from More than Forty Angels Going from Biotech Founder to Biotech Executive: Compare and Contrast Jeff Behrens Recommends that Prospective Biotech Founders Get Experience at Big Biotech Companies Parting Thoughts from Sean Kevlahan, PhD Topics: biotech, partnerships with strategics, pivot, returns, IP / patents, Mass Challenge

Opportunities in Angel-Scale Biotech: Learn More Founder Justin Real tells us how Realplay Sports survived the COVID pause and set itself up to serve booming customer demand in 2022 and 2023. In the 2-year hiatus, Realplay expanded the type customers it can address and brought in partners to enrich its product offering. An inspiring chat with a compelling founder. Sponsored by Purdue University entrepreneuship and Peter Fasse, patent attorney at Fish & Richardson. Highlights: Sal Daher Welcomes Back Justin Real, Founder of Portfolio Company Realplay Sports Justin Real Diplomatically Notices That There’s a Lot Less Sal “...Realplay is a technology company with a goal of solving a problem for the amateur sports ecosystem.” Realplay Serves Mainly the 14 to 18-year-old Players Being Recruited. Younger Players Who Aspire to Be Recruited Also Forms a Significant Clientele “When they're watching the kid playing in the tournament venue, they can just enjoy the game instead of being there with the camera, taking a video...” The Impact of the Angel Invest Boston Podcast in Connecting Justin Real and Launchpad Erik Bullen Was an Early Believer in Realplay Sports 2020 Was Supposed to Be a Big Growth Year for Realplay, Then COVID Hit The Big March 13th Event in Arizona that Never Happened Potential Partners Began to Reach Out During COVID to Explore Collaborations Connections Made During COVID Led to a Much Richer and Diverse Product Offering that Made Realplay More Compelling to Users How Realplay Stayed Alive in 2020 Rapsodo Now Provides Pitch and Ball Tracking on Realplay In 2021, Realplay Still Managed to Grow Despite All the Uncertainties Realplay Expects 2022 to Set a Record for Growth in Revenues Jason Real Makes the Point that Zoom Lowers the Cost of Taking a Meeting with Someone and thus Makes People More Willing to Take Meetings Realplay’s Current Challenge Is Stepping Up to the Expected Tripling of Business in 2023 Peter Thiel’s Advice on Follow-On Investments Parting Thoughts from Justin Real, Founder of Realplay Sports: Gratitude + Watch Out for That Curveball  Topics: product, raising money, partnerships with strategics, COVID

The promise of angel-scale biotech: Learn More Founder & VC Aaron Michel of 1984.vc on portfolio companies, Reggora, Faimarkit and Relevize and how they exemplify the firm’s approach to seed-stage investing. Aaron also gives Sal a mind-expanding suggestion on angel-scale biotech. Compelling & jargon-free! Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish & Richardson Sal Daher, CFA Introduces Aaron Michel, Venture Capitalist at 1984.VC Reggora: “...they're just enabling the lenders to do an appraisal almost in an Uberized fashion, in a much faster and much more efficient way than it used to be.” Brian & Will of Reggora Sold $5 Million of Real Estate in their Senior Year at Boston University A Dorm Room Business Helped the Founders of Reggora Discover a Scalable Business Opportunity Fairmarkit Is Automating the Enterprise Procurement Process Relevize – Helps Companies Sell Better via Channel Partners Relevize Gives Channel Partners Digital Advertising Content and Then Monitors Performance Aaron Michels Founded PathSource to Help People Find the Right Career Sal’s Partner Bob Smith Was Not Cut Out for the Law But was a Natural Entrepreneur “Both my parents are professors. They were both professors at Boston University. Both had started companies.” CareerPath’s Pivot How Aaron Michel Crossed Over from Being an Operator to Being a VC “Ideally, you can choose your competitor set.” “For B2B actually, we are open to investing pre-launch, as long as there's a product.” Aaron Michel’s Mind-Expanding Suggestion for How Better to Address the Opportunities of Angel-Scale Biotech “VCs tend to overvalue their advice and undervalue their introductions.” Topics: founding story, competition, venture capital  

Why angel-scale biotech is so promising: Learn More Qiuyan Xu, PhD is a statistician, an entrepreneur and a colleague at Walnut. We talked about the startups she has invested in, her immigrant journey and the work she does at Gravitate AI (https://www.gravitate.ai) Sponsors: Purdue University entrepreneurship & Peter Fasse, patent attorney at Fish & Richardson Highlights: Sal Daher Introduces Qiuyan Xu, PhD, Statistician, Entrepreneur and Angel Investor Qiuyan Xu Talks About Her Investment in AOA Diagnostics Qiuyan Xu Talks About Her Investment in Octagon Therapeutics What Sal Daher Looks for in an Academic Founder Qiuyan Xu Wonders About the Long Holds in Life Science Investments “It's an important thing to remember now that the early-stage, angel-scale life science investing is really, really just beginning to take off.” “There are some angels who have done very successfully, with just a handful of companies.” “Weeding out the obvious losers. I think it makes a lot of sense.” We Still Know Surprisingly Little in the Life Sciences Qiuyan Xu Came to the US in 2003 to Study Statistics at UC Davis “...I got my PhD in 2008, in statistics, in the middle of a recession.” What Drove Qiuyan Xu to Become an Entrepreneur Qiuyan Xu’s Company Is Gravitate AI (https://www.gravitate.ai/) Gravitate AI Helps with Data Cleaning & Automation as Well as Customizing Open-Source AI Solutions How Qiuyan Xu Became an Angel Investor Contagious Enthusiasm Qiuyan Xu’s Advice to Angel Investors “You're urging angels to step right in, but at the same time, exercise control and have a budget.” Advice to Founders Topics: robotics / AI, discovering entrepreneurship, angel investing strategies  

Angel-scale biotech is hot: Learn More Slater Victoroff founded Indico Data in his dorm room at Olin in 2012. Two years later Indico had gone through Techstars and was VC-backed. Hear the story of how making deep learning accessible to enterprise customers led to massive growth. Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish & Richardson Highlights: Sal Daher Introduces Slater Victoroff, Founder and CTO of Indico Data Indico Was Founded in a Dorm Room in 2012, Two Years Later They Raised $3 million in an Oversubscribed Round Machine Learning Is Programming with Data Rather than Code Deep Learning Is Characterized by a Focus on Unstructured Data i.e., Text, Audio and Images Indico’s Original Aim Was to Make Deep Learning Accessible to Software Developers Slater Victoroff Founded Indico Because Most Innovation in Deep learning Was Driven by Industry Indico’s Experience at Techstars Semyon Dukach Saw Promise in Indico Others Did Not “...Techstars really helped us understand was that we were real.” Why Slater Victoroff Gave Up the CEO Role The Shift to Enterprise Clients and Massive Growth Stellar Customer Satisfaction Metrics Was the Secret Slater Victoroff Was an Unlikely Founder About Hiring Machine Learning Talent Slater’s Work at .406 Ventures What Sets Olin College Apart How Textbooks Empower the Self-Directed Learners Why Slater Victoroff Does Not Invest in the Life Sciences Parting Thoughts from Slater Victoroff Topics: founding story, robotics / AI, Techstars  

Angel-scale biotech is exploding: Learn More Practicing urologist and founder Jeremy Wiygul, MD believes millions of people are suffering needlessly due to the inadequate delivery of effective treatment, among these his own wife. Pelex aims to use new technology to integrate existing resources and greatly enhance patient outcomes for people with pelvic floor problems such as incontinence. A fun chat with a compelling founder. Sponsors: Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish & Richardson Highlights: Sal Daher Introduces Jeremy Wiygul, MD Founder of Pelex “...up to 60 million Americans are affected by one form or another of pelvic floor disorders.” Pelex Combines a Connected Device and a Telehealth Platform to Provide Effective Care Pelex Intends to Bring Together the Right Provider, the Right Treatment and the Right Delivery of Care Consumer-Grade Pelvic Floor Devices Are Hit or Miss Parallels to Imago Rehab Which Delivers Physical Therapy Remotely via a Connected Device Connected with Jeremy Wiygul via Chrissy Glover of Imago Rehab Jeremy Wiygul’s Own Physical Rehab Informs His Work Why Would a Urologist with a Practice in New Your City Found a Startup? What’s the Innovation Pelex Is Bringing to Market? The Regulatory Strategy to Build Value in the Long Run “...we feel very strongly that our outcomes are going to be above, and significantly better than any other service that's out there.” Strategy with Regards to Intellectual Property The Combination of Practitioner, Care and Delivery Has the Potential to Build a Brand Based on Dramatic Improvements in Outcomes for Patients If the Wife of an Urologist Struggles to Get the Right Care in Her Husband’s Specialty, There’s Obviously a Problem Contact jeremy@pelex-med.com if You Have the Problem or Want to Help Exit Strategy The Power of Bringing the Right Technology to Market at the Right Time Learn More at https://pelexhealth.com/ Thanks Chrissy Glover of Imago Rehab for the Introduction to Jeremy Wiygul Topics: biotech, discovering entrepreneurship, software

Erik Bullen, founder, angel and listener, gives us an overview of his startups and how his life has changed since exiting his last company. Highlights: Sal Daher Introduces Erik Bullen, Angel, Founder & Listener Erik Bullen Is Excited About Focal Point, a SaaS Solution in the Procurement Space “It's one of those stories where he could not find a solution to actually solve this problem so... I'm going to create my own solution and build my own company.” Anders Lillevik of Focal Point Was on the Fence About Joining Techstars Atlanta; It Turned Out Well “What Focal Point does is it integrates a lot of the other silos that are out there.” How Erik Bullen Reshaped His Work Life After Selling His Company “...Guidely is targeting...alternate methods of mental health and personal development and using techniques, not clinical techniques...” Cyberthentic: “...a very novel way to prevent email business compromise...” “It's actually complementary to some of the other cybersecurity solutions out there.” Meenta Grew Exponentially During COVID Gabor Bethelendy’s First Startup Failed; a Few Months Later Gabor Was Starting Meenta Gabor Bethlendy Met His Co-Founder Stephan Smith Because Their Sons Got into Fisticuffs at School Realplay: Simplifying Sports Videos for Tournament Venues Realplay Cameras Record Tournament Play, Its Algorithm Finds and Tags Crucial Parts Erik Bullen and Justin Real of Real Play Developed a Close Advisory Relationship Erik Bullen Was Born in Bremen to a German Mom and an American Dad Biked 10 Miles in His Suit During a Virginia Summer to Get to a Job Interview! “"Looks like you need a beer." He goes over a fridge gets me a beer. This is a very different interview than I was expecting.” “It was formative for me in terms of really loving starting things and building things as well.” "Hey, by the way, your van is smoking." Erik Bullen Worked in Amsterdam in Digital Marketing; World Wildlife Fund & International Red Cross Were Clients Erik Bullen Eventually Headed Global Services at Brightcove Sal Daher Asks Erik Bullen About Obstacles to Investing in Biotech Knowledge About the Science and the Industry Is the First Obstacle Long Investment Hold and Capital Requirements Are the Second Obstacle “Life Sciences would be great, but you know what, I can't spread myself too thin either.” “I'm big on finding solutions and supporting cancer research...but I have not invested in a company that focuses on that area.” Sal Daher’s Perspective on the Knowledge Problem in the Life Sciences Why Sal Daher Is Bullish on Daphne Zohar and PureTech Health Why Sal Daher Is Focusing on Angel-Scale Biotech RockStep Solutions and VistaPath Bio Are Examples of Software Eating the Life Sciences “Most of these companies are going to end up being bought by a strategic.” The Angel Invest Boston Podcast Introduced Erik Bullen to Angel Investing Compare & Contrast: Walnut Ventures, Launchpad and TBD Angels Erik Bullen’s Parting Thoughts

Angel-scale biotech is taking off: Learn More Susan Conover of Piction Health, is building an AI to improve results and reduce costs in the treatment of skin conditions. Piction has amassed 500,000 diagnosed images and is already helping primary care physicians interpret skin problems in patients. A great chat with an inspiring founder.   Highlights:   Sal Daher Thanks Sponsors Purdue University Entrepreneurship and Peter Fasse, Patent Attorney at Fish & Richardson Sal Daher Introduces Susan Conover of Piction Health Susan Conover’s History with Melanoma and the Scarcity of Dermatologists "What are opportunities for identifying skin diseases and how can technology help?" “...we help elevate every doctor to have that visual expertise of a dermatologist...” Piction Health’s Data Set Includes 500,000 Diagnosed Images with a Variety of Skin Tones “We're, right now, focused on rashes.” “...what makes the most sense to start with is a buyer who's realizing the value of our product now.” “We estimate we can save these organizations, risk-bearing organizations, $160,000 per doctor per year.” Piction Health Is Looking for Providers Who Have at least 50% of the Downside Risk of Patient Costs Looking for a Product Manager and a Senior Machine Learning Engineer Piction Health Is Partnering with a Big Provider to Develop Its Product Offering Scaling Dermatology from 40 Patients per Day to 40,000 Patients per Day The Value of Techstars and MassChallenge to Piction Health Parting Thoughts – Advice to People Who Are on “Survival Mode” at Work  Topics: Mass Challenge, Techstars, robotics AI, discovering entrepreneurship

Angel-scale biotech is hot! Learn More Psychiatrist and founder Jacqueline Olds on her startup and her mission to fight loneliness in America. Words of wisdom and lots of laughs in this interview that could actually make your life better. Brought to you by: Purdue University entrpreneurship, and Peter Fasse, patent attorney at Fish & Richardson   Highlights:   Sal Daher Introduces, Jacqueline Olds, M.D., Psychiatrist and Founder Jacqueline and Her Husband, Founded GoodLux Technologies to Help Treat Depression without Drugs They Created a Device and an App to Help People with Bright Light Therapy “We thought this would be a wearable that would remind people that there was a way to treat their depression without using “ Sal Used the GoodLux Sunsprite to Help His Newborn Grandson Sleep Through the Night “The people who lived in places with an abundance of sun sometimes got seasonal depression, because they couldn't stand going outside in the summer, and they were inside like moles.” Overcoming Loneliness, Practical Strategies for Finding Connection “...a huge percentage of our patients were lonely but they were all embarrassed to admit it, and were thinking that they were the only ones who felt lonely and left out...” Marriage in Motion: “...what lasting marriages look like.” The Lonely American: Why Americans in Particular Experience so Much Social Isolation “There's that undercurrent of American culture that essentially says you're going to be okay if you're on your own...” “Fewer people are getting married and fewer people are living with other people and everybody acts like that's a reasonable thing to do...when it's bad for your health mentally and physiologically.” “Part of the reason psychotherapy can be helpful, is that you bring out these secrets that you felt terrible about and they sound positively measly when you talk them over with an actual human being...” Americans Are Confiding in Fewer and Fewer People Opportunities for Human Interaction Are Disappearing Due to Technology and Other Factors The Down Side of Interacting with People Only When You Feel Like It “To live in an environment where you have so many ties means you have very few choices...” The Thickly Connected Social Environment of Sal’s Home Town in Brazil Social Life of Grad Students in Boston in the Mid-1960s The Town of Roseto and Its Notable Cardiac Health and Longevity Outcomes The Secret of Longevity Was the Close Social Bonds of the Community The Down Side of Close-Knit Communities The Paradox of Choice: How Too Many Options Keep Us from Deciding “...COVID has given us all a chance to reset and try to achieve balance in a new way because we were forced to calm down and give up some of our favorite enjoyments like going to restaurants or going to plays or going to concerts.” Psychiatrist Jacqueline Olds’ Suggestion for Connecting Younger People Working Remotely “Lots of slightly anxious, lonely, depressed people decide, "I don't want anyone to know how needy I feel, so I'm just going to take my light down.’” The Value of Witnesses in Marriage “...making sure those three o'clock thoughts are just that, nonsense. At eight o'clock in the morning, with coffee in front of you, just, "It's nothing. It was just a nightmare."” Love, Shopping & Cocaine “When a college student comes in and they're looking all miserable and cold and unhappy with their studies, and then they find somebody that they're starting to fall in love with and suddenly they're full of smiles. You can just see the dopamine practically showing on their face.” Parting Thoughts from Jacqueline Olds, M.D., the Wise Psychiatrist

The Promise of Angel-Scale Biotech: Learn More The miracle-working CEO of portfolio company Finetune Learning is back to tell us about the latest developments in applying artificial intelligence in educational assessments. We also got into remote work and explored how to support younger workers in creating professional networks while working remotely. Sponsored by: Purdue University entrepreneurship Peter Fasse, patent attorney at Fish & Richardson Highlights: Sal Daher Expresses Gratitude for His Sponsors: Purdue University Entrepreneurship and Peter Fasse, Patent Attorney at Fish & Richardson Sal Daher Introduces Steve Shapiro the Miracle-Working CEO of Finetune Learning Finetune Learning Uses Technology to Support the Creation of Great Educational Assessments Version 1.0 of Finetune Made It Easier to Grade Essays Consistently – A 2X Improvement Finetune Version 2.0 Is More B2B – It Is Assisting in the Effective Creation Content for Educational Assessment Making Assessment Writers 10X More Effective “The other product that we have that scans the text, then classifies and tags it, does it in two orders of magnitudes more than a team of humans. Let's throw away the 2X to 10X and start saying 100x, 200x.” “...we never said this is something that replaces a human. We believe that strongly. We always say this is something that's going to augment humans who are really good at this.” Pre-Trained Systems Will Revolutionize Adaptive Learning “In most cases, we're not a full solution. We are either a widget or an intel inside a larger solution with a large partner that's a multi-billion-dollar” "I went into this because I actually hated school and you're throwing me back into a classroom....” Old-Time Adaptive Learning “That missing 10%, they have to be trained and they're not there because the teaching methods don't fit their learning style.” “...there's a ton of Gen Z and Millennial founders out there that are starting to create companies in education technology...” Unexpected Source of Talent for Cybersecurity Finetune Driven to Remote Work Before the Pandemic Due to the Difficulty of Competing for Talent with Amazon and Google in Kendall Square Lessons on Managing a Remote Workforce – Learned from GitLab The Right Approach to Company Culture How a Founder Learned to Get Along with Her Co-Founder How Younger Workers Are Disadvantaged by Remote Work How to Help Younger Workers Build Social Networks? A Question for Jacqueline Olds, M.D. How Do We Reskill Angel Investors to Help Build Life Science Startups? A Happy Outcome from Zoom School Steve Shapiro’s Parting Thoughts Topics: edtech, management, robotics / AI, software

The Promise of Angel-Scale Biotech: Learn More SPVs (Special Purpose Vehicles) are democratizing startup investing. In this interview with Jeremy Neilson, founder of Assure.co, we discussed how founders and angels can benefit from these increasingly economical platforms and what they mean for the future. Highlights: Sal Daher Introduces Jeremy Neilson Co-Founder of Assure.co Sal and Jeremy Met at an Event Held by Jason Calacanis in 2019 “...the engine of a large number of groups that do angel investing.” Use Cases for SPVs (Special Purpose Vehicles) It Used to Be Very Pricey to Set Up and SPV – No Longer A Way for Angels to Increase the Diversity of their Portfolio co Is helping Democratize Investing in Private Assets co Focuses on Accredited Investors – Does Not Do Equity Crowdfunding The Founding Story of Assure.co “...AngelList called my co-founder, Katie, and I and said, "Can you guys figure out how to do funds in bulk?"” Sal Daher Advises People Not to Make the Mistake He Made in Creating His Own SPVs – A Lot of Work! “He's the pope of angel investing podcasts. I'm just a cardinal, or perhaps a bishop.” Biotech Too Is Being Democratized “...we're seeing in the ecosystem is a very large shift away from thinking strictly financial.” “No longer is it a very small niche of uberwealthy or venture funds, now it's the entire ecosystem of accredited investors now have the opportunity to participate.” io and Curesology “We have seen clients come and say, "I want to donate my carry to a good cause."” “Carta, AngelList, Assure.co were those three that got started all together back about eight, nine years ago.” Cheaper SPVs Are Helping to Give Access to More Diverse Founders by Broadening the Reach of Investors Sal Compares Two Robotic Glove Startups Three Decades Apart to Demonstrate How Much the Startup Ecosystem Has Developed “Her life is going to be so much easier in starting that company than it was for Chrissy Glover’s starting Imago Rehab [today] and way, way easier than Beth Marcus’ starting EXOS back in the early '90s.” “Assure.co is helping to lower the dead weight of a startup rocket that's trying to reach escape velocity.” Wisdom from Waseem Daher of Pilot.com on Angels & Cap Tables SPV Pricing at Assure.co co Powers Jason’s Syndicates, EquityZen and Forge Among Many Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish & Richardson Topics: discovering entrepreneurship, fin tech, angel investing strategies

The Opportunitites in Angel-Scale Biotech: https://syndicate.angelinvestboston.com/en-us/the-surge-of-opportunities-in-angel-scale-biotech The dynamic duo of founder Adam Martel and super angel Christopher Mirabile are back on the podcast to report on the sale of Gravyty and to discuss Adam’s new startup, Givzey. Highlights: Gravyty Created a New Category How COVID Affected Gravyty Merging Gravyty and Graduway Sal Compares the Gravyty Exit and the Mavrck Exit Selling a Startup to a Private Equity Firm Adam Martel Talks About his New Startup, Givzey “Because we're experts in data, we've seen if you make a gift to your alma mater for the last 20 years, odds are that you're going to make a gift in the 21st year.” “...the ability to understand the market and to understand the timing of the market; is the market ready for this, has been shown to be a very important predictor of success in ventures.” Sal Daher Shifts the Conversation to the Life Sciences “...you don't meet many academics who aren't pretty sharp. When you think about it, many of them are really quite good at project management.” Being Coachable Is Essential for First-Time Academic Founders “...Michael Jordan wasn't coachable, but I think he would tell you that he heard everything people said.” AceUp, the Executive Coaching Platform Purdue University Entrepreneurship and Peter Fasse, Patent Attorney at Fish & Richardson Sponsor the Podcast Hilltop Biosciences and Founder Amanda Drobnis QSM Diagnostics Kalion: Bioengineering Microorganisms to Produce Valuable Compounds KnipBio – Another Use for Microorganisms Piction Health – AI for Skin Topics: product, exits, biotech

Why Sal Is Bullish on Biotech: Click Here Adam de Sola Pool, a highly successful pioneer in green tech investing in the 1990s, now sees huge opportunities in blue tech.  Don’t miss this fascinating tour of ocean technologies conducted by an engaging investor/guide. Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish & Richardson Highlights: Sal Daher Welcomes Back Fellow Angel Investor Adam Pool “...he finds the kind of opportunities [in ocean tech] today that he saw in cleantech back in the 1990s.” The Surge in Aquaculture Creates Massive Opportunities for Investors, including Angel Investors Adam Pool Recently Invested in BioFeyn Which Is Making the Feeding of Farmed Fish More Efficient “...we're transforming the food part of the $3 trillion business that is the ocean economy.” Sal Sees Parallels Between the Explosion of Opportunities in Biotech and in Blue Tech. Cool: Seatrec and its Ocean-going Electric Charging Stations Cool: Making Fish Food Out of Mealworms and Black Soldier Fly Larvae Cool: Ocean Rainforest Produces Kelp Used to Control Bovine Flatulence Cool: Reel Data Uses Facial Recognition for Salmon. IKYN! Interested Angel Investors Can Contact Blue Angels https://sea-ahead.com/blue-angels Cool: Oyster Tracker Offers Digital Tracking of Oysters from the Sea Bed to the Dinner Plate Cool: Fish in Fashion – You Won’t Believe This! “I'm so glad that I violated my format and went blue instead of bio.” Many Exits in Blue Tech Interesting Companies Protecting the Oceans but also Creating Work Opportunities for Displaced Workers Several VC Funds Being Raised – Investable by Angels Sal Daher Sees Adam de Sola Pool as a Visionary Who Is Also Practical Topics: product, exits, portfolio, venture capital

Why Sal Is Bullish on Biotech VeraMorph has a new way to deliver insoluble drugs by mouth. Founder Doug Godfrin, PhD elucidates the promise of accessing the 85% of drugs that are not soluble. Does VeraMorph pass Sal Daher’s screen for angel-scale biotech? Listen and find out. Sponsors: Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson Highlights: Sal Daher, CFA Introduces Doug Godfrin, PhD, Founder of VeraMorph A New Way to Deliver Drugs Orally How VeraMorph Gets Around the Solubility Problem VeraMorph’s Approach Is Janus-like: Shelf Stable but Available Where Needed The Decade of Biotech & VeraMorph AltrixBio: Gastric Bypass Surgery in a Pill Sal Daher’s Biotech Screen: Strong Patents “VeraMorph actually owns the patents outright for this platform technology.” “We've really taken a totally different perspective with this class of material by focusing on immediate release via oral delivery...” Sal Daher’s Biotech Screen: Capable Academic Founder Sal Daher’s Biotech Screen: Is it Angel-Scale? US$1 Million Will Get VeraMorph to Production for Pre-Clinical Trials “...chances of reaching that next set of milestones is 90% or above.” Doug Godfrin Is Collaborating with Colin Minchom, PhD, a Veteran of Drug Development US$ 2 to 3 million More Will Take VeraMorph to Clinical Stage, Doug Predicts Sal and Doug Look at the Odds of Getting to Clinical Stage Sal Daher’s Biotech Screen: Do Strategics Care? Sal Daher’s Biotech Screen: Platform Technology? Sponsors Purdue University and Peter Fasse Are Founder-Friendly The Upside of Failure in Biotech This guy calls me up, "Saleh, let's get together at Darwin's in Cambridge. I want to talk to you about a new company." Doug Godfrin’s Parting Thoughts Topics: biotech